Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Alimera Sciences Inc

ALIM
Current price
5.57 USD -0.01 USD (-0.18%)
Last closed 5.58 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 291 280 064 USD
Yield for 12 month +58.69 %
1Y
3Y
5Y
10Y
15Y
ALIM
21.11.2021 - 28.11.2021

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia. Address: 6310 Town Square, Alpharetta, GA, United States, 30005

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.67 USD

P/E ratio

Dividend Yield

Current Year

+80 754 000 USD

Last Year

+54 129 000 USD

Current Quarter

+23 011 000 USD

Last Quarter

+26 306 000 USD

Current Year

+61 170 000 USD

Last Year

+46 152 000 USD

Current Quarter

+16 573 000 USD

Last Quarter

+19 640 000 USD

Key Figures ALIM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 10 219 000 USD
Operating Margin TTM -10 %
PE Ratio
Return On Assets TTM -0.58 %
PEG Ratio
Return On Equity TTM -197.04 %
Wall Street Target Price 5.67 USD
Revenue TTM 90 219 000 USD
Book Value 0.78 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 69.9 %
Dividend Yield
Gross Profit TTM 51 999 000 USD
Earnings per share -0.25 USD
Diluted Eps TTM -0.25 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin -23.74 %

Dividend Analytics ALIM

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALIM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 15.11.2019
Dividend Date 15.11.2019

Stock Valuation ALIM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 117.6471
Enterprise Value Revenue 2.9481
Price Sales TTM 2.2821
Enterprise Value EBITDA -213.5159
Price Book MRQ 4.0028

Financials ALIM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ALIM

For 52 weeks

2.61 USD 5.65 USD
50 Day MA 3.86 USD
Shares Short Prior Month 94 683
200 Day MA 3.66 USD
Short Ratio 0.32
Shares Short 229 307
Short Percent 1.12 %

Dynamics of changes in the value of assets

B

BIJ

33.05 EUR Bijou Brigitte modische Accessoires Aktiengesellschaft -0.76 (-2.07%)
Detailed analytics
E

ED4

10.05 EUR EDAG Engineering Group AG +0.05 (+0.5%)
Detailed analytics
4

4078

2 830.00 JPY Sakai Chemical Industry Co Ltd -0.22 (-1.22%)
Detailed analytics
R

R7E1

0.26 EUR CYBIN INC. -0 (-0.45%)
Detailed analytics
3

3176

1 593.00 JPY Sanyo Trading Co Ltd -0.04 (-0.44%)
Detailed analytics